Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is a highly immune-suppressive tumor with a low response rate to single checkpoint blockade therapy. ETS homologous factor (EHF) is a tumor suppressor in PDAC. Here, we report a novel function of EHF in pancreatic cancer immune microenvironment editing and eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jing, Jiang, Wenna, Zhao, Kaili, Wang, Hongwei, Zhou, Tianxing, Bai, Weiwei, Wang, Xiuchao, Zhao, Tiansuo, Huang, Chongbiao, Gao, Song, Qin, Tai, Yu, Wenwen, Yang, Bo, Li, Xin, Fu, Danqi, Tan, Wei, Yang, Shengyu, Ren, He, Hao, Jihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400540/
https://www.ncbi.nlm.nih.gov/pubmed/30733283
http://dx.doi.org/10.1084/jem.20180749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400540/
https://www.ncbi.nlm.nih.gov/pubmed/30733283
http://dx.doi.org/10.1084/jem.20180749

Ejemplares similares